MedTrace Logo

SYNERGY China: Assess SYNERGY Stent in China

NCT02499692 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2020-09-16

Study results available
· View outcomes & findings →

Summary

Prospective, multicenter, single-arm study, enroll 100 patients in no more than 10 sites across China, the primary endpoint is Technical success.

Conditions

Interventions

DEVICE

SYNERGYTM Coronary Stent System

SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Yalin Han · Shenyang Northern Hospital (The General Hospital of Shenyang Military Region)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-10-31
Completion
2017-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02499692 on ClinicalTrials.gov